Skip to main content
. 2019 Nov 12;19:1088. doi: 10.1186/s12885-019-6322-9

Fig. 5.

Fig. 5

Utilities of FGF19 as a biomarker for recurrence prediction. (a) Cumulative RFS rate based on serum FGF19 levels before ablation therapy. (b) Changes in the serum FGF19 levels after the ablation therapy against HCC. (c) Relationship between non-normalization and an unexpected increase in the FGF19 levels after the ablation therapy and early recurrence